Seminars in Oncology
Volume 31, Issue 2 , Pages 206-219, April 2004

Gastrointestinal cancer in older patients

  • Peter C Enzinger

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    • Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
    • Department of Medicine, Harvard Medical School, Boston, MA, USA
    • Corresponding Author InformationAddress reprint requests to Peter C. Enzinger, MD, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115 USA
  • ,
  • Robert J Mayer

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    • Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
    • Department of Medicine, Harvard Medical School, Boston, MA, USA

Abstract 

More than two thirds of gastrointestinal cancers occur in persons 65 years of age or older. The symptoms and presentation in these older individuals appear similar to those of persons of younger age. Although treatments for these cancers have been developed primarily in younger patients, greater expertise over time has permitted similarly safe and efficacious therapy to be extended to older age groups. The majority of gastrointestinal cancers are located in the colon and rectum. Preventative strategies for colorectal cancer are quickly evolving, with the beneficial effect of long-term use of aspirin and estrogen having their greatest impact in the elderly population. The increased acceptance of colonoscopy for screening patients for colorectal cancer will be of greatest benefit in older individuals, who have a higher incidence of proximal neoplasms than younger individuals. Adjuvant therapy for both colon and rectal cancer is underutilized in elderly patients, despite such life-saving treatments resulting in similar survival prolongation, as well as toxicity profiles, as in their younger counterparts. There is a paucity of information concerning the treatment of elderly patients with other gastrointestinal malignancies.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(03)00669-9

doi:10.1053/j.seminoncol.2003.12.031

Seminars in Oncology
Volume 31, Issue 2 , Pages 206-219, April 2004